January 05, 2018
Reproductive disorder drugmaker Repros Therapeutics Inc. has been hit with a stockholder suit in Delaware federal court that seeks to block a proposed $30 million acquisition by Allergan PLC unless Repros releases more information on how it valued itself ahead of the deal.